Robert W. Sobol, Ph.D.
Chief, Molecular and Metabolic Oncology Program
USA Mitchell Cancer Institute
1660 Springhill Avenue
Mobile, Alabama 36604
Research in the Sobol lab focuses on the mechanism of base excision repair, PARP and NAD+ metabolism in human cells and the convergent role of these enzymes and pathways in response to environmental Geno toxins and chemotherapy. A major goal in the lab is to use biochemical, genetic and imaging modalities to study the protein complexes of the base excision repair pathway that respond to DNA damage induced by Geno toxins and chemotherapy and how this pathway affects the regulation of cellular metabolism via ADP-ribosylation signaling and alterations in NAD+ metabolism. Dr. Sobol has been continually funded by grants from NIH (NCI) as well as those from the American Cancer Society, the Susan G. Komen Breast Cancer Foundation, the Brain Tumor Society, the Pittsburgh Foundation and the Elsa U. Pardee Foundation for Cancer Research, among others.
-- B.S. in Chemistry, Allegheny College, 1982
-- M.A. in Chemistry, Temple University, 1987
-- Ph.D., Biochemistry, Temple University, 1991
-- Laboratoire de Biochimie des Protéines, UA CNRS 1191, Université Montpellier II, Montpellier, France, Selective mRNA degradation by antisense oligonucleotide-2,5A chimeras, 1991-1993
-- Institute of Genetics, Univ. of Cologne, Summer Collaborative study: Mouse Genetics and Mouse Gene knockouts, 1994
-- Carolina Program in Molecular Biology & Biotechnology, UNC-Chapel Hill, Gene Targeting in ES cells and Transgenic Mice, 1997
-- UTMB and NIEHS, NIH, Reverse Genetics of Mammalian Base Excision Repair, 1993-2002
-- MBL Special Topics Course, Woods Hole, Mass., Molecular Biology of Aging, 2004
-- National Cancer Institute, Visiting Researcher, Bethesda, Md., Dept. of Biochemistry, 1990-1991
-- NIH – CNRS, Postdoctoral Fellow, UA CNRS 1191, Université Montpellier II, Montpellier, France, 1991-1993
-- Institute of Genetics, Univ. of Cologne Visiting Scientist/Collaborator, Germany, Laboratory of Prof. K. Rajewsky, 1994
-- Sealy Center for Molecular Science UTMB, Assistant Scientist, Galveston, Texas, 1993-1996
-- National Institute of Environmental Health Research Fellow Sciences (NIH); Laboratory of Structural Biology, 1996-2002
-- Dept. of Pharmacology & Chemical Biology Assistant Professor, University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine, 2002-2012
-- Molecular Pharmacology Graduate Program, 2004-2014
-- The Faculty of the University of Pittsburgh School of Medicine Scholarly Project, 2005-2014
-- The Graduate Faculty for the University of Pittsburgh and Carnegie Mellon University Medical Scientist Training Program, 2005-2014
-- Director, UPCI Lentiviral Facility, 2007-2014
-- Department of Human Genetics Assistant Professor, University of Pittsburgh, School of Public Health, 2008-2013
-- Dept. of Pharmacology & Chemical Biology Associate Professor w/tenure, University of Pittsburgh Cancer Institute, University of Pittsburgh, School of Medicine, 2012-2014
-- Department of Human Genetics Associate Professor w/tenure, University of Pittsburgh, School of Public Health, 2013-2014
-- Visiting Lecturer (Mechanisms of DNA Repair) Visiting Lecturer, University Immersion Program; Sichuan University, Chengdu, China, 2014
-- Point Clear Charities Professor of Oncologic Sciences, Chief, Molecular & Metabolic Oncology Program, Abraham A. Mitchell Distinguished Investigator, Director, USAMCI GEED Lab, Director, USAMCI Technology Development facility, USA Mitchell Cancer Institute, October 2014
-- Dept. of Pharmacology & Chemical Biology Adjunct Professor, University of Pittsburgh, School of Medicine, November 2014
-- Point Clear Charities Professor of Oncologic Sciences; Chief, Molecular & Metabolic Oncology; Abraham A. Mitchell Distinguished Investigator; USA Mitchell Cancer Institute -- 2015-present
Honors and Memberships
Member, AAAS. 1993 – Present
Member, AACR, 2003 – Present
Member, ASM, 2003 – Present
Member, ASCB, 2004 – Present
Member, EMS, 2004 – Present
Member, American Chemical Society, 2006 – Present
Member, International Society for Cell & Gene Therapy of Cancer, 2009 – Present
Member - ASPET (American Society for Pharmacology and Experimental Therapeutics) 2010 – Present
1. Fouquerel, E., Goellner, E.M., Yu, Z., Gagné, J.P., Barbi de Moura, M., Feinstein, T., Wheeler, D., Redpath, P., Li, J., Romero, G., Migaud, M., Van Houten, B., Poirier, G.G., Sobol, R.W., "ARTD1/PARP1 Negatively Regulates Glycolysis by Inhibiting Hexokinase 1 Independent of NAD(+) Depletion.” (2014) Cell Rep. Sep 25;8(6):1819-31. Epub 2014 Sep 15. PMID: 25220464; PMCID: PMC4177344.
2. Fang, Q., Inanc, B., Schamus, S., Wang, X.H., Wei, L., Brown, A.R., Svilar, D., Sugrue, K.F., Goellner, E.M., Lan, L., Vens, C., and Sobol, R.W., “HSP90 regulates DNA repair via the interaction between XRCC1 and DNA Polymerase β”. Nat Commun. (2014) Nov 26;5: 5513 doi: 10.1038/ncomms6513. PMID: 25423885; PMCID: PMC4246423.
3. Quiñones, J.L., Thapara, U., Yub, K., Fang, Q., Sobol, R.W. and Demple, B. “Enzyme Mechanism-Based, Oxidative DNA-Protein Crosslinks Formed with DNA Polymerase ß in vivo” (2015) Proceedings of the National Academy of Sciences of the United States of America. July 14; 112(28)8602-7. PMID: 26124145; PMCID: 4507217.
4. Agnihotri, S., Burrell, K., Remke, M., Golbourn, B., Chornenkyy, Y., Buczkowicz, P., Gajadhar, A., Fernandez, N.A., Clarke, I.D., Barszczyk, M.S., Pajovic, S., Ternamian, C., Head, R., Sabha, N., Sobol, R.W., Taylor, M.D., Rutka, J.T., Jones, C., Dirks, P.B., Zadeh, G., and Hawkins, C., “An ATM-MPG axis promotes therapeutic resistance in pediatric glioblastoma” (2014) Cancer Discovery. Oct; 4(10): 1198-213. Epub 2014 Aug 6.PMID: 25100205: PMCID: PMC4184920.
5. Mao P., Joshi, K., Li, J., Santana-Santos, L., Luthra, S., Chandran, U.R., Benos, P.V., Smith, L., DeWang, M., Hu, B., Cheng*, S.Y., Sobol*, R.W., Nakano*, I. “Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3” (2013) Proceedings of the National Academy of Sciences of the United States of America. (*Corresponding Author) May 21; 110(21)8644-9. PMID: 23650391; PMCID: PMC3666732.
6. Goellner, E.M., Grimme, B., Brown, A.R., Lin, Y., Wang, X.H., Sugrue, K.F., Mitchell, L., Trivedi, R.N., Tang, J.B., and Sobol, R.W. “Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair” (2011) Cancer Research, Mar 15;71(6):2308-17; PMID: 21406402; PMCID: PMC3077901.
7. Tang, J.B., Svilar, D., Trivedi, R.N., Wang, X.H., Goellner, E.M., Moore, B., Hamilton, R.L., Banze, L.A., Brown, A.R., and Sobol, R.W. “N-methylpurine DNA glycosylase and DNA Polymerase ß modulate BER inhibitor potentiation of glioma cells to temozolomide” (2011) Neuro-Oncology, May;13(5):471-86; PMID: 21377995; PMCID: PMC3093332.
© 2017 USA Health System